Precigen/$PGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ticker

$PGEN
Primary listing

Industry

Biotechnology

Employees

143

Precigen Metrics

BasicAdvanced
$463M
-
-$0.56
1.82
-

What the Analysts think about Precigen

Analyst ratings (Buy, Hold, Sell) for Precigen stock.

Bulls say / Bears say

Analysts have issued a 'Moderate Buy' rating for Precigen, with an average price target of $7.00, indicating potential upside from current levels. (etfdailynews.com)
Institutional investors, such as Charles Schwab Investment Management Inc., have increased their holdings in Precigen, suggesting confidence in the company's prospects. (defenseworld.net)
Precigen's recent $79.0 million private placement offering is expected to extend its cash runway well into 2026, supporting the anticipated commercial launch of PRGN-2012 in the second half of 2025. (stocktitan.net)
HC Wainwright has lowered its Q1 2025 earnings per share estimates for Precigen, now expecting a loss of ($0.08) per share, down from the previous estimate of ($0.04). (defenseworld.net)
JPMorgan Chase & Co. reduced its holdings in Precigen by 4.4% during the fourth quarter, potentially indicating decreased confidence in the company's performance. (defenseworld.net)
Precigen reported a net loss of $24.0 million ($0.09 per share) in Q3 2024, compared to a net loss of $19.8 million ($0.08 per share) in Q3 2023, reflecting widening losses. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Precigen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Precigen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PGEN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs